Investigating how the MECOM gene affects high-risk leukemia
Official title: Functionally dissecting MECOM gene regulation in high-risk leukemia
Funded at Harvard Medical School · NIH-11221397 · Data updated 2026-11-12
This study is looking at how a gene called MECOM affects acute myeloid leukemia (AML) to help find better treatments for patients with this challenging type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $36,918 |
| NIH project number | 5F31CA287658-02 |
| Project ID | NIH-11221397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with high-risk genetic profiles.
✕Less likely to help
Patients with low-risk forms of leukemia or those not diagnosed with acute myeloid leukemia may not benefit from this research.
What this research studies
This research focuses on understanding the role of the MECOM gene in acute myeloid leukemia (AML), a type of cancer with a poor prognosis. By creating a specialized cell-line model, researchers can control the degradation of MECOM to observe its effects on gene expression and cell behavior. The study aims to uncover the mechanisms by which MECOM influences leukemia development and how this knowledge could lead to improved treatments for patients with high-risk forms of AML.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve outcomes for patients with high-risk leukemia.
How similar studies have gone: Previous research has shown promise in targeting gene regulation in leukemia, suggesting that this approach could yield significant insights.
Where this research is happening
-
Harvard Medical School
Boston, United States Active
Researchers
- Principal investigator: Fleming, Travis J — Harvard Medical School
- Study coordinator: Fleming, Travis J
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.